Lynx1 Capital Management
Latest statistics and disclosures from Lynx1 Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ALPN, CABA, MRUS, TCRX, CCCC, and represent 78.64% of Lynx1 Capital Management's stock portfolio.
- Added to shares of these 9 stocks: ALPN (+$27M), CCCC (+$12M), STOK (+$6.6M), GHRS, AUTL, PASG, CABA, NKTR, BNOX.
- Reduced shares in these 4 stocks: Cymabay Therapeutics (-$15M), MRUS, ZURA, DBVT.
- Sold out of its positions in Cymabay Therapeutics, DBVT, ZURA.
- Lynx1 Capital Management was a net buyer of stock by $38M.
- Lynx1 Capital Management has $254M in assets under management (AUM), dropping by 68.21%.
- Central Index Key (CIK): 0001910456
Tip: Access up to 7 years of quarterly data
Positions held by Lynx1 Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Lynx1 Capital Management
Lynx1 Capital Management holds 15 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Alpine Immune Sciences (ALPN) | 28.6 | $73M | +58% | 3.8M | 19.06 |
|
| Cabaletta Bio (CABA) | 18.8 | $48M | 2.1M | 22.70 |
|
|
| Merus N V (MRUS) | 12.3 | $31M | 1.1M | 27.50 |
|
|
| Tscan Therapeutics (TCRX) | 12.0 | $31M | 5.2M | 5.83 |
|
|
| C4 Therapeutics Com Stk (CCCC) | 7.0 | $18M | +207% | 3.1M | 5.65 |
|
| Stoke Therapeutics (STOK) | 6.1 | $16M | +72% | 3.0M | 5.26 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 4.7 | $12M | +36% | 1.9M | 6.44 |
|
| Gh Research Ordinary Shares (GHRS) | 4.2 | $11M | +66% | 1.8M | 5.80 |
|
| Kinnate Biopharma (KNTE) | 1.9 | $4.7M | 2.0M | 2.37 |
|
|
| Silence Therapeutics Ads (SLN) | 1.6 | $4.1M | 236k | 17.37 |
|
|
| Theseus Pharmaceuticals | 1.1 | $2.8M | 702k | 4.05 |
|
|
| Pieris Pharmaceuticals (PIRS) | 0.7 | $1.8M | 9.8M | 0.18 |
|
|
| Bionomics Ads (BNOX) | 0.5 | $1.2M | 824k | 1.48 |
|
|
| Nektar Therapeutics (NKTR) | 0.4 | $1.1M | +9% | 1.9M | 0.56 |
|
| Passage Bio (PASG) | 0.2 | $383k | +99% | 379k | 1.01 |
|
Past Filings by Lynx1 Capital Management
SEC 13F filings are viewable for Lynx1 Capital Management going back to 2021
- Lynx1 Capital Management 2023 Q4 filed Feb. 14, 2024
- Lynx1 Capital Management 2023 Q3 filed Nov. 14, 2023
- Lynx1 Capital Management 2023 Q2 filed Aug. 14, 2023
- Lynx1 Capital Management 2023 Q1 filed May 15, 2023
- Lynx1 Capital Management 2022 Q4 filed Feb. 14, 2023
- Lynx1 Capital Management 2022 Q3 filed Nov. 14, 2022
- Lynx1 Capital Management 2022 Q2 filed Aug. 15, 2022
- Lynx1 Capital Management 2022 Q1 filed May 16, 2022
- Lynx1 Capital Management 2021 Q4 filed Feb. 14, 2022